Medgenics, Inc. (NYSE Amex:MDGN) Files An 8-K

Medgenics, Inc. (NYSE Amex:MDGN) announced today that it has been approved for listing on the NASDAQ Global Market, continuing to trade under the symbol “MDGN.” Trading on the NASDAQ Global Market is expected to commence on October 21, 2016. The Company’s common stock will continue to trade on the NYSE Amex until the market close on October 20, 2016.

Story continues below

Mike Cola, Chief Executive Officer Medgenics, commented, “We are pleased to announce our listing on the NASDAQ Global Market. We believe the move to NASDAQ will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to leading biotech and healthcare institutional investors.”

About Medgenics, Inc.

Medgenics, Inc. is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGTTM (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform. For more information, visit the Company’s website at www.medgenics.com.

An ad to help with our costs